Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Professor; Intramural Faculty, Koch Institute

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Koch Institute for Integrative Cancer Research


Judy Teixeira



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Transforming ovarian cancer care by targeting minimal residual disease. Jazaeri, AA, Grisham, R, Knisely, A, Spranger, S, Zamarin, D, Hillman, RT, Lawson, BC, Burns, KH, Lee, S, Westin, SN et al.. 2023. Med 4, 755-760.
    doi: 10.1016/j.medj.2023.08.004PMID:37951209
  2. Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2. Horton, BL, D'Souza, AD, Zagorulya, M, McCreery, CV, Abhiraman, GC, Picton, L, Sheen, A, Agarwal, Y, Momin, N, Wittrup, KD et al.. 2023. JCI Insight 8, .
    doi: 10.1172/jci.insight.172728PMID:37669107
  3. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression. Nguyen, KB, Roerden, M, Copeland, CJ, Backlund, CM, Klop-Packel, NG, Remba, T, Kim, B, Singh, NK, Birnbaum, ME, Irvine, DJ et al.. 2023. Elife 12, .
    doi: 10.7554/eLife.85263PMID:37548358
  4. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Lax, BM, Palmeri, JR, Lutz, EA, Sheen, A, Stinson, JA, Duhamel, L, Santollani, L, Kennedy, A, Rothschilds, AM, Spranger, S et al.. 2023. Proc Natl Acad Sci U S A 120, e2300895120.
    doi: 10.1073/pnas.2300895120PMID:37487077
  5. A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Ely, ZA, Mathey-Andrews, N, Naranjo, S, Gould, SI, Mercer, KL, Newby, GA, Cabana, CM, Rideout, WM 3rd, Jaramillo, GC, Khirallah, JM et al.. 2024. Nat Biotechnol 42, 424-436.
    doi: 10.1038/s41587-023-01783-yPMID:37169967
  6. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Bhagchandani, SH, Vohidov, F, Milling, LE, Tong, EY, Brown, CM, Ramseier, ML, Liu, B, Fessenden, TB, Nguyen, HV, Kiel, GR et al.. 2023. Sci Adv 9, eadg2239.
    doi: 10.1126/sciadv.adg2239PMID:37075115
  7. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Zagorulya, M, Yim, L, Morgan, DM, Edwards, A, Torres-Mejia, E, Momin, N, McCreery, CV, Zamora, IL, Horton, BL, Fox, JG et al.. 2023. Immunity 56, 386-405.e10.
    doi: 10.1016/j.immuni.2023.01.010PMID:36736322
  8. MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Chatterjee, F, Spranger, S. 2023. Semin Immunol 66, 101710.
    doi: 10.1016/j.smim.2023.101710PMID:36640616
  9. Something old, something new: The marriage of PD-1 and IL-2. Horton, BL, Spranger, S. 2023. Immunity 56, 8-10.
    doi: 10.1016/j.immuni.2022.12.012PMID:36630920
  10. Once upon a prime: DCs shape cancer immunity. Zagorulya, M, Spranger, S. 2023. Trends Cancer 9, 172-184.
    doi: 10.1016/j.trecan.2022.10.006PMID:36357313
More Publications



Photo credit: Kelsey Montgomery